Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Core Insights - Alterity Therapeutics presented data from its bioMUSE study on Multiple System Atrophy (MSA) at the 35th International Symposium on the Autonomic Nervous System, focusing on disease progression and neuroimaging advancements [1][2]. Group 1: Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA [1][8]. - The company's lead asset, ATH434, is currently being evaluated in two Phase 2 clinical trials for MSA [8]. Group 2: Study Findings - The bioMUSE study aims to track MSA progression and has enrolled approximately 20 individuals with clinically probable or established MSA [4]. - The study utilized advanced neuroimaging techniques, including machine learning, to track brain volume changes in MSA patients, correlating these changes with clinical disease progression [2][3]. - The MSA Atrophy Index (MSA-AI) was introduced as a potential biomarker for assessing MSA progression, derived from specific brain regions affected by the disease [3]. Group 3: Disease Context - MSA is a rare neurodegenerative disease affecting at least 15,000 individuals in the U.S., characterized by autonomic nervous system failure and movement impairment [5]. - Currently, there are no approved therapies to slow MSA progression, highlighting the need for effective disease-modifying treatments [5].